Intravenous immunoglobulin in the management of a rare cause of hemolytic disease of the newborn: Anti-SARA antibodies.

Abstract

Hemolytic disease of newborn (HDN) is a condition that develops in a fetus, when the IgG molecules produced by the mother pass through the placenta and attack the fetal red blood cells. HDN can occur due to Rh and ABO incompatibilities between the mother and the fetus as well as due to other allo-immune antibodies belonging to Kell (K and k), Duffy (Fya), Kidd (Jka and Jkb), and MNS (M, N, S, and s) systems. Role of intravenous immunoglobulin in management of HDN is not clear.SARA red blood cell antigen, first discovered in 1990 is a low frequency antigen. We report, a multiparous female whose pregnancy was complicated by HDN due to anti-SARA antibodies requiring both exchange transfusion and intravenous immunoglobulin. The response was sustained after intravenous immunoglobulin (IVIG) rather than after exchange transfusion.

• Authors: Rohini Venkataraman, Kamran Yusuf
• Journal: Journal of neonatal-perinatal medicine (J Neonatal Perinatal Med) Vol. 10 Issue 3 Pg. 329-332 ( 2017) ISSN: 1878-4429 [Electronic] Netherlands
• PMID: 28854515 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies
• Immunoglobulins, Intravenous
• Immunologic Factors
• Isoantigens
• SARAH antigen

Topics

• Antibodies (immunology)
• Erythroblastosis, Fetal (drug therapy, immunology)
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Immunologic Factors (therapeutic use)
• Infant, Newborn
• Isoantigens (immunology)
• Male